TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MetaVia ( (MTVA) ) has shared an update.
On November 6, 2025, MetaVia Inc. released an updated corporate presentation detailing its ongoing clinical trials and future milestones. The company is making significant progress with its DA-1726 and Vanoglipel (DA-1241) candidates, showing promising results in weight loss and glucose control, which could enhance its market position. MetaVia is also planning further clinical trials and regulatory submissions, potentially increasing shareholder value and impacting the treatment landscape for obesity and MASH.
The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.
MetaVia’s overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and no revenue generation. The technical analysis indicates weak market momentum, and negative valuation metrics highlight the stock’s high-risk profile. Although recent positive trial results provide some potential for future growth, significant strategic changes are necessary for the company to achieve financial stability and investor confidence.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. operates in the biotechnology industry, focusing on developing next-generation therapeutics for cardiometabolic diseases, particularly targeting obesity and metabolic-associated steatohepatitis (MASH). The company is advancing its pipeline with novel treatments like DA-1726, a GLP1R/GCGR dual agonist, and Vanoglipel (DA-1241), aiming to address significant unmet needs in these areas.
Average Trading Volume: 1,944,151
Technical Sentiment Signal: Sell
Current Market Cap: $26.13M
For detailed information about MTVA stock, go to TipRanks’ Stock Analysis page.